Objective:To systematically investigate the main active components,targets,target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder(YFBP)of Zhang Zhongjing,a Chinese physician of Eastern Han Dynasty o...Objective:To systematically investigate the main active components,targets,target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder(YFBP)of Zhang Zhongjing,a Chinese physician of Eastern Han Dynasty of China(3 century A.D.)using the method of network pharmacology.Methods:The active components of YFBP were identified from several databases(TCMSP,TCM Database@Taiwan and TCMID).The potential active compounds were screened based on oral bioavailability and drug-like index in the TCMSP database.DrugBank,TCMSP,and TCMID database searches were performed to predict target-related diseases.Biological functions and KEGG pathway outcomes of all potential targets were analyzed using the DAVID database.Results:A total of 24 active compounds of YFBP,133 related targets,and 305 potential related diseases were obtained.These results showed that YFBP may treat inflammation,pain,and cancer.The functional enrichment analysis indicated that YFBP probably exerts its therapeutic effects by regulating neuroactive ligand-receptor interactions,the TNF signaling pathway,and the PI3K-Akt signaling pathway.Conclusion:This study provides preliminary confirmation that YFBP has the great potentials to treat inflammation,pain,and tumors,which supports Zhang Zhongjing’s original intention to treat intestinal carbuncle with ancient prescription YFBP,but also provides a scientific basis for its treatment in the malignant tumors.展开更多
Objective:To explore the mechanism of Yiyi Fuzi Baijiang p owder in treatment of ulcerative colitis in Coix Lacryma-jobi based on network pharmacology and molecular docking technology.Methods:Search for Yiyi Fuzi Baij...Objective:To explore the mechanism of Yiyi Fuzi Baijiang p owder in treatment of ulcerative colitis in Coix Lacryma-jobi based on network pharmacology and molecular docking technology.Methods:Search for Yiyi Fuzi Baijiang powder’s active ingredient by traditional Chinese medicine database and analysis platform system pharmacology,Genecards,Uniprot database and Cytoscape software were used to construct the active component-ulcerative colitis disease target network,and gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed,Autodock Vina was used for molecular docking verification.Results:Quercetin,luteolin,kaempferol,chrysin,macroanol B,β-sitosterol,stigmasterol,deltoan and rhizoctonine may play a role in the treatment of ulcerative colitis.KEGG pathway enrichment analysis showed that Yiyi Fuzi Baijiang p owder mainly involved i nterleukin-17 signaling pathway and cancer pathway,among which the key targets were PTGS2,HSP90AA1 and CASP3 and had a good binding activity with 10 main active components.Conclusion:The treatment of ulcerative colitis by Yiyi Fuzi Baijiang p owder may be mainly through quercetin,luteolin,macroanol B,β-sitosterol and other chemical components involved in cancer pathway,i nterleukin-17 signaling pathway acting on PTGS2,HSP90AA1,CASP3 and other disease targets in response to inorganic substances,response to cytokines and other biological processes f actor receptor binding and other molecular functions to achieve the purpose of treating u lcerative colitis.展开更多
目的:观察溃疡性结肠炎(ulcerative colitis,UC)大鼠Treg/Th17细胞的变化特点及薏苡附子败酱散对Treg/Th17的影响.方法:采用2,4,6-三硝基苯磺酸(2,4,6-trinitrob enzenesulfonic acid solution,TNBS)法制作UC大鼠模型,随机分为4组:正常...目的:观察溃疡性结肠炎(ulcerative colitis,UC)大鼠Treg/Th17细胞的变化特点及薏苡附子败酱散对Treg/Th17的影响.方法:采用2,4,6-三硝基苯磺酸(2,4,6-trinitrob enzenesulfonic acid solution,TNBS)法制作UC大鼠模型,随机分为4组:正常组、模型组、薏苡附子败酱散(Fuzi Baijiang powder,YFB)组、阳性药美沙拉嗪缓释颗粒(positive drug mesalazine SR Granules,5-ASA)组.治疗14 d后取标本,观察肉眼形态学改变及显微镜下黏膜损伤情况,采用ELISA法测定血清中白介素-17(interleukin-17,IL-17)、IL-10活性;采用实时荧光定量PCR法检测结肠组织中RORγt、Foxp3 mRNA的表达.结果:与正常组相比,模型组大鼠结肠黏连伴肠腔扩张,肠壁增厚,组织水肿、充血,有溃疡形成.病理切片HE染色后在光镜下观察,部分黏膜出现充血坏死,肉芽组织形成,隐窝丢失,炎症细胞浸润.与模型组相比,YFB组及5-ASA组镜下病理组织评分明显降低(3.00±0.82 vs 8.00±0.82 vs 12.50±1.29,均P<0.05),血清IL-17、IL-10含量有显著差异(22.26±3.95 vs 39.62±4.26 vs 53.86±2.51,48.72±1.05 vs 44.16±1.90 vs 38.88±0.80,均P<0.05),YFB及5-ASA组间比较,YFB能显著降低IL-17含量,增加IL-10含量(均P<0.05).YFB及5-ASA组结肠组织RORγt、Foxp3 mRNA含量与模型组对比有显著差异(1.29±0.05 vs 1.32±0.87 vs 1.80±0.54;2.81±0.17 vs 2.00±0.20vs 0.47±0.04,均P<0.05),且与5-ASA组比较,YFB组RORγt mRNA含量明显下降(P<0.05),Foxp3 mRNA含量显著增加(P<0.05).结论:应用TNBS法成功建立了UC的大鼠模型.YFB能改善UC模型大鼠的炎症症状,能明显的降低结肠组织中RORγt mRNA的表达,降低血清IL-17的含量,提高Foxp3 mRNA的表达,增加IL-10的含量,YFB影响Treg/Th17细胞数量及功能是其发挥治疗溃疡性结肠炎大鼠炎症作用的机制之一.展开更多
目的观察加味薏苡附子败酱散对复杂性肛瘘术后愈合的影响。方法将2018年8月—2019年6月在石家庄市中医院手术治疗的60例复杂性肛瘘患者随机分为治疗组和对照组各30例,术后对照组患者常规换药,治疗组在常规换药基础上给予加味薏苡附子败...目的观察加味薏苡附子败酱散对复杂性肛瘘术后愈合的影响。方法将2018年8月—2019年6月在石家庄市中医院手术治疗的60例复杂性肛瘘患者随机分为治疗组和对照组各30例,术后对照组患者常规换药,治疗组在常规换药基础上给予加味薏苡附子败酱散口服,治疗15 d。观察2组患者术后不同时间点创面分泌物、疼痛、肉芽生长情况,比较2组治疗总有效率、创面愈合时间及不良反应发生情况。结果术后3 d 2组患者创面分泌物、疼痛、创面肉芽组织生长评分以及创面面积比较差异均无统计学意义(P均>0.05),随着时间延长,2组创面分泌物、疼痛、创面肉芽组织生长评分以及创面面积均明显下降(P均<0.05),各时间点时上述检测指标治疗组均明显低于对照组(P均<0.05);术后15 d,治疗组治疗总有效率为96.7%(29/30),明显高于对照组的73.4%(22/30),差异有统计学意义(P<0.05);治疗组创面愈合时间明显短于对照组(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论加味薏苡附子败酱散可有效促进复杂性肛瘘术后患者创面愈合,缩短愈合时间,且安全。展开更多
基金This research is supported by National Natural Science Foundation of China(81603434),Shanghai Natural Science Foundation Project(17ZR1438800)and Shanghai Health Planning Commission Project(ZY3-RCPY-1-1001,zybz-2017029).
文摘Objective:To systematically investigate the main active components,targets,target-related diseases and action mechanism of Yiyi Fuzi Baijiang powder(YFBP)of Zhang Zhongjing,a Chinese physician of Eastern Han Dynasty of China(3 century A.D.)using the method of network pharmacology.Methods:The active components of YFBP were identified from several databases(TCMSP,TCM Database@Taiwan and TCMID).The potential active compounds were screened based on oral bioavailability and drug-like index in the TCMSP database.DrugBank,TCMSP,and TCMID database searches were performed to predict target-related diseases.Biological functions and KEGG pathway outcomes of all potential targets were analyzed using the DAVID database.Results:A total of 24 active compounds of YFBP,133 related targets,and 305 potential related diseases were obtained.These results showed that YFBP may treat inflammation,pain,and cancer.The functional enrichment analysis indicated that YFBP probably exerts its therapeutic effects by regulating neuroactive ligand-receptor interactions,the TNF signaling pathway,and the PI3K-Akt signaling pathway.Conclusion:This study provides preliminary confirmation that YFBP has the great potentials to treat inflammation,pain,and tumors,which supports Zhang Zhongjing’s original intention to treat intestinal carbuncle with ancient prescription YFBP,but also provides a scientific basis for its treatment in the malignant tumors.
基金support plan of Shaanxi Province“Leading Talents in Scientific and Technological Innovation”program(TZ0326)Key Research and development projects of Shaanxi Province.
文摘Objective:To explore the mechanism of Yiyi Fuzi Baijiang p owder in treatment of ulcerative colitis in Coix Lacryma-jobi based on network pharmacology and molecular docking technology.Methods:Search for Yiyi Fuzi Baijiang powder’s active ingredient by traditional Chinese medicine database and analysis platform system pharmacology,Genecards,Uniprot database and Cytoscape software were used to construct the active component-ulcerative colitis disease target network,and gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed,Autodock Vina was used for molecular docking verification.Results:Quercetin,luteolin,kaempferol,chrysin,macroanol B,β-sitosterol,stigmasterol,deltoan and rhizoctonine may play a role in the treatment of ulcerative colitis.KEGG pathway enrichment analysis showed that Yiyi Fuzi Baijiang p owder mainly involved i nterleukin-17 signaling pathway and cancer pathway,among which the key targets were PTGS2,HSP90AA1 and CASP3 and had a good binding activity with 10 main active components.Conclusion:The treatment of ulcerative colitis by Yiyi Fuzi Baijiang p owder may be mainly through quercetin,luteolin,macroanol B,β-sitosterol and other chemical components involved in cancer pathway,i nterleukin-17 signaling pathway acting on PTGS2,HSP90AA1,CASP3 and other disease targets in response to inorganic substances,response to cytokines and other biological processes f actor receptor binding and other molecular functions to achieve the purpose of treating u lcerative colitis.
文摘目的:观察溃疡性结肠炎(ulcerative colitis,UC)大鼠Treg/Th17细胞的变化特点及薏苡附子败酱散对Treg/Th17的影响.方法:采用2,4,6-三硝基苯磺酸(2,4,6-trinitrob enzenesulfonic acid solution,TNBS)法制作UC大鼠模型,随机分为4组:正常组、模型组、薏苡附子败酱散(Fuzi Baijiang powder,YFB)组、阳性药美沙拉嗪缓释颗粒(positive drug mesalazine SR Granules,5-ASA)组.治疗14 d后取标本,观察肉眼形态学改变及显微镜下黏膜损伤情况,采用ELISA法测定血清中白介素-17(interleukin-17,IL-17)、IL-10活性;采用实时荧光定量PCR法检测结肠组织中RORγt、Foxp3 mRNA的表达.结果:与正常组相比,模型组大鼠结肠黏连伴肠腔扩张,肠壁增厚,组织水肿、充血,有溃疡形成.病理切片HE染色后在光镜下观察,部分黏膜出现充血坏死,肉芽组织形成,隐窝丢失,炎症细胞浸润.与模型组相比,YFB组及5-ASA组镜下病理组织评分明显降低(3.00±0.82 vs 8.00±0.82 vs 12.50±1.29,均P<0.05),血清IL-17、IL-10含量有显著差异(22.26±3.95 vs 39.62±4.26 vs 53.86±2.51,48.72±1.05 vs 44.16±1.90 vs 38.88±0.80,均P<0.05),YFB及5-ASA组间比较,YFB能显著降低IL-17含量,增加IL-10含量(均P<0.05).YFB及5-ASA组结肠组织RORγt、Foxp3 mRNA含量与模型组对比有显著差异(1.29±0.05 vs 1.32±0.87 vs 1.80±0.54;2.81±0.17 vs 2.00±0.20vs 0.47±0.04,均P<0.05),且与5-ASA组比较,YFB组RORγt mRNA含量明显下降(P<0.05),Foxp3 mRNA含量显著增加(P<0.05).结论:应用TNBS法成功建立了UC的大鼠模型.YFB能改善UC模型大鼠的炎症症状,能明显的降低结肠组织中RORγt mRNA的表达,降低血清IL-17的含量,提高Foxp3 mRNA的表达,增加IL-10的含量,YFB影响Treg/Th17细胞数量及功能是其发挥治疗溃疡性结肠炎大鼠炎症作用的机制之一.
文摘目的观察加味薏苡附子败酱散对复杂性肛瘘术后愈合的影响。方法将2018年8月—2019年6月在石家庄市中医院手术治疗的60例复杂性肛瘘患者随机分为治疗组和对照组各30例,术后对照组患者常规换药,治疗组在常规换药基础上给予加味薏苡附子败酱散口服,治疗15 d。观察2组患者术后不同时间点创面分泌物、疼痛、肉芽生长情况,比较2组治疗总有效率、创面愈合时间及不良反应发生情况。结果术后3 d 2组患者创面分泌物、疼痛、创面肉芽组织生长评分以及创面面积比较差异均无统计学意义(P均>0.05),随着时间延长,2组创面分泌物、疼痛、创面肉芽组织生长评分以及创面面积均明显下降(P均<0.05),各时间点时上述检测指标治疗组均明显低于对照组(P均<0.05);术后15 d,治疗组治疗总有效率为96.7%(29/30),明显高于对照组的73.4%(22/30),差异有统计学意义(P<0.05);治疗组创面愈合时间明显短于对照组(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论加味薏苡附子败酱散可有效促进复杂性肛瘘术后患者创面愈合,缩短愈合时间,且安全。
